Although most children with ALL can be cured by chemotherapy approaches, allogeneic hematopoietic cell transplant (HCT) therapy offers a better chance of cure to selected high-risk patients in first remission and most children who relapse. Although transplant-related mortality has decreased significantly in the past decade, relapse remains high after HCT for ALL; developing strategies to decrease relapse and improve survival are vital. Recent studies have shown that relapse risk can be accurately defined using measurements of minimal residual disease (MRD) both pre-and post-HCT and by knowing whether patients get GVHD in the first 2 months after transplant. With these risk definitions in hand, investigators are now applying novel agents and immunotherapeutic methods in attempt to lower MRD before transplant and modulate the GVL effect after transplant. With powerful new immunological approaches coming on line, the transplant process itself will likely expand to include pre and/or post-HCT interventions aimed at reducing relapse.
INTRODUCTION
Improved approaches to chemotherapy continue to increase longterm survival of children with ALL, which now approaches 90%. 1 A portion of that success is a result of defining children in first remission at highest risk and performing allogeneic hematopoietic cell transplantation (HCT) to prevent relapse. In addition, for children who relapse after standard chemotherapy, HCT provides cure for a significant percentage of patients who achieve a second remission. TRM has decreased markedly over the past 15 years, 2, 3 and with improvements in outcomes with cord blood and haploidentical approaches over the past decade, 4 almost all eligible patients can receive HCT with lower risk.
In spite of these advances, relapse rates in children with highrisk ALL undergoing HCT remain high (25-40%) . 5 Those at the highest risk can now be identified, and studies aimed at decreasing relapse are underway. Powerful new immunological approaches combined with a better understanding of the importance of the GVL effect offer promise of decreasing relapse in these high-risk children.
In this review, we will define the current best and promising future practices of HCT for high risk ALL by discussing, (1) when and why to consider HCT, (2) how we can use minimal residual disease (MRD) and the occurrence of GVHD after HCT to define populations where intervention may decrease relapse and (3) how novel approaches used before or after HCT might be used to improve post transplant survival.
When and why should we transplant children with ALL? A portion of children with relapsed and refractory ALL achieve improved survival after allogeneic HCT due to the GVL effect. For example, decreased relapse in ALL has been associated with the occurrence of GVHD after HCT. 6 It is likely that long-term immune surveillance instilled by the new stem cell graft is responsible at least in part for the advantage in survival in comparison with chemotherapy alone. Currently, the rationale for offering an allogeneic HCT as the preferred therapy for a child with ALL in first remission is based upon a predicted 5-year EFS with current chemotherapy of o 45%. This EFS was selected based on an expected 5-year EFS of ⩾ 60% for an HLA-identical HCT in complete remission 1 (CR1). Recent data reveal that children with ALL who have low MRD before transplant have an expected EFS of 70-75%. 5 Thus, an expected 5-year EFS of ⩽ 55% with chemotherapy may be a more appropriate selection point for HCT based on current outcomes.
Very high-risk groups with some evidence to support the use of HCT in first remission include subgroups of patients with Ph+ALL, hypodiploidy ( o44 chromosomes), induction failure, persistent MRD after consolidation and possibly selected high-risk infants with MLL rearrangements (Table 1) . With the recent Children's Oncology Group (COG) and European Intergroup (EsPhALL) studies of Ph+ALL, chemotherapy for Ph+ALL has improved significantly. On the COG AALL0031 study, with 7 years of follow up, the 4-year DFS for intensive chemotherapy in Cohort 5 plus imatinib is 75 ± 9% compared favorably with related HCT (64 ± 11%) and unrelated HCT (64 ± 16%; P = 0.77). Although the AALL0031 protocol has led to excellent long-term outcomes, the approach included very high doses of ifosfamide (9 g/m 2 ), cytarabine (36 g/m 2 ), cyclophosphamide (11 g/m 2 ) and nine doses of high-dose methotrexate (45 g/m 2 ) with toxicities approaching those of HCT. The conclusion of this study is that for Ph+ALL that responds well to induction therapy with a tyrosine kinase inhibitor (TKI), intensive chemotherapy with tyrosine kinase inhibitor offers an equivalent outcome, likely with lower long-term toxicity compared with HCT. 7 Follow-up trials are attempting to decrease the intensity of the chemotherapy backbone and assess the role of second generation tyrosine kinase inhibitors. HCT is restricted to resistant patients (persistent MRD or induction failure).
Hypodiploid ALL continues to have a poor prognosis with o40% 5-year EFS in patients with o44 chromosomes. 8 Recent results from the AALL0031 study after 6 years of follow-up reveal a 4-year DFS for HCT of 62 ± 11% and chemotherapy of 50 ± 11% (P = 0.54). It has been shown recently that there are two major genetic categories heavily represented in hypodiploid patients-a group with p53 mutations and another with tyrosine kinase and Ras-pathway lesions. 9 Differences in outcome with these groups are just beginning to be explored and further elucidation of the specific pathways involved in these patients, followed by targeted therapy may improve survival in the future. Outside of an investigational protocol, HCT is considered a reasonable option for these patients.
Induction failure continues to be an indication for HCT in CR1. A recent paper by Schrappe showed that children over 6 years of age had a significant survival advantage after HLA-identical sibling HCT compared with chemotherapy (59 versus 39%) as well as for T-ALL with a 5-year EFS of 40-45% for any HCT versus 26% for chemotherapy. 10 Evaluation of the induction failure patients treated on the COG AALL0031 HCT had survival of 75 versus 41% for chemotherapy although this was not significant (P = 0.14) due to small patient numbers.
There is strong evidence from several groups that the presence of MRD after induction/consolidation is associated with high rates of relapse. 11, 12 On the basis of such data, St Jude researchers have offered upfront HCT to these patients with excellent results, 13 an approach that is also is being investigated in Europe.
14 Finally, use of HCT for infant leukemia has been investigated by a number of groups. Looking at all infants, there is no evidence of an advantage of HCT over chemotherapy. 15 This analysis included both lower-risk and very high-risk infants, potentially diluting an improvement with HCT for the highest risk subgroup. In that regard, the Interfant group showed that HCT offered an advantage for a subgroup of infants with MLL-rearranged ALL o 6 months of age at diagnosis who had very high white counts. 16 The main thrust of current studies is to use targeted agents in this very poorrisk group. Outside of such a study, very high-risk MLL+ infants o6 months of age at diagnosis may possibly benefit from HCT. Are there other very high-risk ALL groups that should be considered? Patients with iAMP21 have been noted to have high relapse rates with chemotherapy. 17 Intensive therapy including transplantation has led to improved survival in studies from the United Kingdom, but it is unclear whether HCT is needed for patients who become MRD negative early in treatment, 18 and HCT has not been explored in the context of other chemotherapy approaches. Another group with poor outcome is the Ph-like ALL, which is three times more common than Ph+ALL. 19, 20 As we are able to further characterize genetic subgroups with poor outcomes, it is likely that some of these groups will benefit from HCT in CR1.
The prognosis of ALL continues to be poor after relapse. Allogeneic HCT is considered the preferred therapy for any T-ALL with marrow relapse, Ph+ALL relapse, marrow relapses with first remission (CR1) duration of o 36 months, extramedullary relapses with CR1 duration o18 months and ALL relapse with CR1 duration ⩾ 36 months when marrow remains MRD+ after induction. 21 Patients who have a second relapse and can achieve a remission are also considered candidates for HCT. 22 With these possible indications along with ongoing genetic identification of high-risk subtypes of ALL, why should we choose HCT as a possible therapy? Evidence continues to emerge that HCT has a strong immune effect that is important in preventing relapse, and it is important to further define the characteristics and subtypes of ALL that respond best to allogeneic HCT. Similar to examples of ALL relapsing due to demonstrated resistance to specific chemotherapy, ALL relapsing after HCT has been shown to acquire resistance to immune system recognition. 23 As we learn more about immune recognition and tolerance in ALL, we should be able to more effectively apply HCT and related therapies. Figure 1 shows mechanisms likely associated with relapse after HCT. Biological studies further dissecting these mechanisms will be vital in improving HCT outcomes.
Impact of MRD and GVHD on relapse-defining patients who need more than HCT The presence of molecularly measured MRD just before HCT has been shown to predict relapse risk of ALL in children. 24 More recent studies confirm that detection of ALL MRD by flow cytometry preHCT can also predict relapse, [25] [26] [27] although the effect on outcome varies among the reports ( Table 2) . The ASCT0431 study, recently completed through the COG/Pediatric Blood and Marrow Transplant Consortium (PBMTC) showed that relapse rates were threefold higher in patients with pretransplant MRD levels ⩾ 0.1% by flow cytometry. Similarly, detection of MRD by flow after HCT has been associated with a 3.3-fold increase in risk of relapse. 28 The presence of a GVL effect in ALL has been an area of some controversy. Observations of a poor response to DLI given for ALL relapsed after HCT, 29, 30 and high relapse rates when patients go to transplant with active disease 31 suggest a relatively weak effect. However, a preponderance of studies over the past 20 years, 6, [32] [33] [34] [35] [36] including studies in pediatric and young adult patients (Table 2) , [37] [38] [39] suggest an effect of both acute and chronic GVHD in decreasing relapse. The ASCT0431 study provided further evidence for a key role of GVL in decreasing relapse and curing children with ALL, demonstrating that the occurrence of grades I-III aGVHD led to a hazard ratio of 0.44 for relapse (P = 0.04) and an twofold improvement in EFS (P = 0.01). Of note, de novo cGVHD by itself did not have an effect on outcomes; however, cGVHD occurring after acute GVHD was noted to provide further protection against relapse (aGVHD plus cGVHD hazard ratio = 0.14 (P = 0.05) compared with no GVHD). Abbreviations: CR = complete remission; MRD = minimal residual disease.
Novel HCT for pediatric ALL Abbreviations: aGVHD = acute GVHD; cGVHD = chronic GVHD; CI = confidence interval; HCT = hematopoietic cell transplantation; MRD = minimal residual disease; RR = risk ratio. Given that the two most important determinants of risk for any given individual for relapse and failure after ALL transplant are (1) a pre-HCT factor (presence of MRD) and (2) a post-HCT factor (occurrence of aGVHD), how can one define a population at highenough risk to require an intervention? Analysis of ASCT0431 showed that the large majority of children who were MRD +preHCT who developed aGVHD did not relapse. Almost 95% of patients developed aGVHD in the first 2 months after HCT. Thus, by approximately day +55-60, patients who do not develop aGVHD can be identified as a group to target for an intervention. The tempo of relapse showed relatively low rates of relapse occurring in the first 200 days after HCT, with a sharp rise in the risk of relapse starting at about day 200 and continuing until day +450. This high risk of relapse occurred in patients who had not experienced aGVHD. Those who were MRD+preHCT and who did not experience aGHVD had the highest risk of relapse (approximately 70%). With these factors noted, patients who were MRD+ and had no aGVHD by day +55 and patients who were MRD − preHCT who became MRD+ at some time post-HCT had rates of failure exceeding 80%, thus defining an ideal population for a trial intervention designed to reduce the risk of relapse. The intervention would need to be performed relatively soon after day +55 in order to combat the increasing rates of relapse that occur after day +200.
Using MRD and aGVHD, there are three general ways to intervene in attempt to prevent relapse ( Figure 2 ). The first and most obvious would be to devise strategies that reduce MRD levels preHCT. Although patients who achieve MRD negativity after the first round of induction have been shown to have improved survival after ALL relapse, 40 it is not clear that those with disease that is resistant and remains MRD+ after 3+ rounds of intensive induction are destined to fail biologically, or whether an additional novel intervention that might render them MRD negative would improve their outcome. Several studies are addressing MRD reduction before HCT, as will be further discussed below (Table 3) .
The other two strategies one could apply post HCT vary based upon whether the agent being tested requires an intact immune system and could be inhibited by post-transplant immunosuppression or whether its mechanism of action is independent of immune effectors and could be given without altering immune suppressive medications. In the latter category are agents such as moxetumomab pasudotox, an investigational recombinant immunoconjugate of an anti-CD22 immunoglobulin variable fragment fused to a toxin. Such agents could be given after HCT in patients identified as very high risk and continued for a maintenance period. One could hypothesize that once the new immune system is fully intact, the patient will have less chance of relapse. Maintenance therapy with such agents using standard timing of immune suppression tapering could bridge a patient to a time of recovery of immunity. One could also imagine that such agents given in a MRD minimal state might reduce residual leukemia to a curative level.
The second approach would involve harnessing the immune system to prevent relapse. This would be necessary for agents that either require immune effector cells (for example, blinatumomab) or if immune suppression would directly effect the efficacy of the agent. Once patients are identified at high risk, withdrawal of immune suppressive agents could be conducted. The correct pacing of such a taper would need to be developed to avoid flare of significant GVHD. Once tapering is complete, as long as significant GVHD has not occurred, the intervention could begin, assuming the immune status of the patient was sufficient for the intervention to work. This approach does increase the risk of GVHD, but Bader and others have shown that rapid withdrawal of immunosuppression can be safely performed in high-risk populations with notable improvement in survival. 41 Novel approaches to prevent relapse after HCT Relapse remains the leading cause of death after allogeneic HCT for the treatment of ALL. 42, 43 Many aspects of the transplant procedure can be modified to reduce risks of relapse, and a variety of promising agents can be added, either before or after HCT.
Pretransplant therapy. The most important factor in predicting post transplant relapse-free survival for children with ALL is pretransplant disease status. Reinduction should always be used to achieve CR before HCT. 44 Myeloablative preparative regimens that include TBI are associated with improved survival outcomes for children with ALL, with a radiation dose-effect seen in some but not all studies. [44] [45] [46] [47] More recently, the depth of remission as measured by MRD has been shown to correlate with posttransplant relapse-free survival. 24, 26 As has been alluded to above, it has not yet been demonstrated whether pretransplant MRD eradication should be a therapeutic objective, but studies designed to address this question are in development. 48 Donor selection. Most current literature suggests that the risk of relapse is generally independent of donor stem cell source (that is, marrow, cord blood, peripheral blood) and donor type (that is, related or unrelated). 49, 50 Mismatching donors and recipients for inhibitory natural killer cell receptors may reduce post-transplant relapse, and is currently being studied specifically to test this hypothesis (Table 3) . [51] [52] [53] Post-transplant immune modulation. Lowering the dose of posttransplant immunosuppression has been shown to reduce the risk of post-transplant relapse in children with ALL. 54 Similarly, rapid post-transplant withdrawal of immunosuppression with or without DLI may be associated with improved relapse-free survival. 41 The COG AALL1331 trial will combine a randomization of blinatumomab in relapsed patients pre-HCT with a preemptive identification of patients at high risk for relapse followed by a taper. Patients noted to be MRD+ either pre-or post-HCT will undergo taper beginning at day +55 if they have not experienced acute GVHD. Once off immune suppression, no further intervention is planned, but the trial will assess the safety of the approach Novel agents and immunotherapeutic approaches. A large number of new agents and immunotherapies have the potential to reduce the risk of relapse after HCT. 55, 56 Clinical trials to assess the efficacy of such novel therapies employed either pre-and post-transplant are in development 57 (Table 3) . A COG trial for children with relapsed ALL who achieve CR after reinduction will include a randomization between blinatumomab and chemotherapy before HCT-a strategy that is aimed to minimize pre-HCT MRD. An MRD reduction trial will be conducted by the PBMTC using moxetumomab pasudotox for patients who are MRD+ after multiple attempts at reinduction, a different population than the COG trial. A third trial running in the Therapeutic Advances in Childhood Leukemia (TACL) Consortium and PBMTC utilizes a Toll-like receptor 9 agonist both pre and post-HCT, laying the groundwork for possible use of this agent to stimulate GVL after HCT. A multicenter trial testing whether favorable killer immunoglobulin-like receptor (KIR) mismatches can lead to less relapse will help clarify if this approach works in ALL and is feasible in a multicenter setting. Finally, trials are underway with anti-CD19 chimeric antigen receptor T cells in B-lineage ALL that will help define the role of chimeric antigen receptor T cells cells either before HCT to achieve an MRD negative state or as a rescue strategy for patients relapsed after HCT. 58 
CONCLUSION
So what is the role of HCT in the treatment of ALL in the current era? Although new targeted immune therapies with chimeric antigen receptor T cells cells, monoclonal antibodies and bispecific antibodies are exciting, at this point, these therapies cannot replace HCT for achievement of lasting anti-ALL immune responses. We anticipate, however, that as we are able to better define high-and low-risk patients preHCT, we will treat lower risk disease with less intensity in an attempt to reduce late effects and target high-risk groups with novel therapies at various time points during the pre and post-HCT process (Figure 3) .
Although we have an improved understanding of resistance pathways in ALL relapse after chemotherapy, we do not yet understand these pathways after HCT. Thus, it is important that studies evaluating the mechanism of relapse after HCT be developed to better understand pathways of resistance and to develop novel therapeutic approaches designed to overcome those mechanisms. Our hope is that over time we will understand immunological pathways of treating ALL well enough that we can intervene effectively and increase rates of cure, while decreasing HCT-related toxicities.
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